
Praxis Precision Medicines rose 66.1% from $197.58 to $328.13, ahead of the S&P 500's +13.3%. Its worst day was Jun 2 (−23.0%), and its low came Nov 20 at $164.09.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Praxis Precision Medicines closed at its lowest level of the year, 17.0% below where the year started.
−13.3% · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
Praxis Precision Medicines shares rose 30.5%, while the S&P 500 rose 0.2%.
+30.5%, the year's best day, on 3M shares, the year's heaviest volume · S&P 500 +0.2%
The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremorPraxis remains on track to submit ulixacaltamide NDA in early 2026 based on
+13.2% · S&P 500 −0.4%
EPS of $-3.50 missed the $-3.08 estimate on $0.00 revenue (est. $256,090.00).
+0.8% · S&P 500 −0.3%
Praxis Precision Medicines shares rose 16.5%, while the S&P 500 rose 2.9%.
+16.5% · S&P 500 +2.9%
EPS of $-3.20 beat the $-3.66 estimate on $0.00 revenue.
−1.4% · S&P 500 −0.3%
Praxis Precision Medicines shares fell 23.0%, while the S&P 500 rose 0.1%.
−23.0%, the year's worst day · S&P 500 +0.1%
EPS of $-2.87 beat the $-3.67 estimate on $0.00 revenue.
+16.0% · S&P 500 −0.2%
EPS of $-3.23 beat the $-3.64 estimate on $0.00 revenue (est. $485,000.00).
+19.9% · S&P 500 +2.4%
Where it ended: a close of $328.13 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 18, 2027 (EPS est. $-3.73, revenue est. $28.5M).
Nothing in the past 12 months.
All PRAX dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PRAX and SPY from Benzinga historical bars. Not investment advice.